News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
April, 2025
April 2025
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
282930  
Talha Badar: Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL here
Photo taken from Talha Badar/X
Jan 1, 2024, 04:39

Talha Badar: Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL here

Talha Badar, Hematologist/Oncologist at Mayo Clinic Comprehensive Cancer Center, posted on X/Twitter:

“Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL here. With median fu of 53 mo DFS and OS are 75.8% and 80.7%! IKZF1 plus and emergence of T315I suggestive of inferior outcome.”

Source: Talha Badar/X

Adult Philadelphia-Positive ALL ALL cancer Dasatinib-Blinatumomab Protocol IKZF1 OncoDaily Oncology T315I Talha Badar
Special Coverage
Blog
Apr 19, 2025, 00:20
Heba ElNokoudy: Comprehensive patient counseling significantly reduces adverse drug events
Blog
Apr 18, 2025, 20:22
Applications are open for the ESMO Research Fellowship
Blog
Apr 18, 2025, 20:12
Caitríona Duggan: Delighted for the opportunity to share our work at MASCC
Blog
Apr 18, 2025, 20:03
Fumiko Ladd Chino: Honored to be invited to speak about financial toxicity
Blog
Apr 18, 2025, 20:02
Estelamari Rodriguez: ACS NLCRT Biomarker Workshop version of brainstorming with the stars
Blog
Apr 18, 2025, 19:54
Sami Mansfield: Fiber, the microbiome, and cancer care
Blog
Apr 18, 2025, 19:49
Eric K. Singhi Discusses Lung Cancer at ASCO 2025
Science
Apr 18, 2025, 19:44
Nirmala Bhoo Pathy: The need for race and ethnicity data in cancer control
Science
Apr 18, 2025, 19:28
Andreas Charalambous: Achieving digital transformation in cancer care across Europe
Blog
Apr 18, 2025, 19:26
SIOG - Older adults deserve better: Let’s close the gap in Cancer Care
Science
Apr 18, 2025, 19:10
Rafael Grochot: The safety and activity of FGFR inhibitors in early-phase clinical trials
Blog
Apr 18, 2025, 18:58
Mission Adaptation and Mission Cancer: Resilient Health Systems for Cancer - ECHoS